Basappa Basappa

2 months ago | nature.com | Shu Chen |Basappa Basappa |Tao Zhu |Vijay Pandey

AbstractTumor dormancy is a substantial clinical obstacle in treatment of estrogen receptor positive mammary carcinoma (ER+MC), contributing to drug resistance, metastatic outgrowth, relapse, and consequent mortality. Preclinical models mimicking clinical anti-estrogen-induced ER+MC dormancy were generated in vivo. Function and a mechanism-based combination treatment were determined in the generated dormancy-like models in vitro, ex vivo, and in vivo.

Dec 9, 2024 | nature.com | Shuwei Zhang |Xi Zhang |Basappa Basappa |Tao Zhu |Vijay Pandey

AbstractIntrinsic and acquired resistance represent major obstacles to optimize outcomes in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted therapy in lung adenocarcinoma (LUAD). Hence, a deeper understanding of EGFR-TKI resistance mechanisms in LUAD will potentially assist in formulating strategies to delay or overcome such resistance. Herein, it was observed that trefoil factor 3 (TFF3) is a crucial mediator of the LUAD EGFR-TKI response.

Sep 10, 2024 | iubmb.onlinelibrary.wiley.com | Basappa Basappa |Bada Yoon |Shreeja Basappa |Omantheswara Nagaraju

1 INTRODUCTION Breast cancer (BC) ranks as the second most prevalent cancer globally and is the fifth leading cause of death, with about 42,000 women succumbing to the disease annually.1 Factors such as hormones, genetics, age, and childbirth contribute to the risk of BC.2, 3 However, the exact pathogenesis of BC remains unclear. Common treatments include chemotherapy, radiation therapy, and surgery, which can lead to various side effects.

Feb 25, 2024 | nature.com | Basappa Basappa |Tao Zhu |Gautam Sethi |Peter E. Lobie

AbstractTherapeutic targeting of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) has remained a significant challenge in clinical oncology. Direct targeting of KRAS has proven difficult, and inhibition of the KRAS effectors have shown limited success due to compensatory activation of survival pathways. Being a core downstream effector of the KRAS-driven p44/42 MAPK and PI3K/AKT pathways governing intrinsic apoptosis, BAD phosphorylation emerges as a promising therapeutic target.

Jan 23, 2024 | pericles.pericles-prod.literatumonline.com | Basappa Basappa |Rashmi Shivakumar |Zhang Xi |Akshay Ravish

Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.